Oral Icotrokinra Reaches 54% PASI 100, a First for a Psoriasis Pill
Icotrokinra reached 54% PASI 100 within roughly a month — a first for an oral psoriasis pill, per Mark Lebwohl, MD, who detailed response timing, nail and palm disease, and monitoring.